However, it has been suggested that anti-VEGFR2 CAR-T cells may also react strongly with some normal human tissues [8]; therefore, prior to TACTIC clinical trials, it is necessary to search for and create tumor vascular injury type CAR-T cells targeting safer molecules with very low expression in normal tissues. Here, KDR is linked to neoplasm.